[eyang1990]

I am a first time poster but long time viewer.  I felt it necessary to respond to this post.  As a cardiologist, we have witnessed many patients concerned about using these types of medications in light of COVID-19.  I can tell you that we don't have any data that indicates increased risk of these medications in COVID-19 patients.  In fact, there are some signals suggested possible benefits, but we will have to await the results of randomized clinical trials.  In general, ACE inhibitors and ARBS should not be discontinued for appropriate clinical indications.  I actually used your post in a presentation I did today on this topic (I hope you don't mind).  I hope this is helpful to the Stanford community.

Here is a link to the video: https://www.acc.org/latest-in-cardiology...t-thinking

Here is a good resource for patients and interested parties published on our cardiology website with up to date information:
https://www.acc.org/latest-in-cardiology...ar-disease

Haha, of course I don't mind, and thank you for your perspective. I'm tickled that your slide included that all-famous Cardboard phrase, "of immense proportions." I haven't watched your presentation yet, but I look forward to at some point, and I'm sure that your reference to my post was something like, "Here's GoodGrief's post--he must undoubtedly be the smartest and handsomest poster of our generation."

GoodGrief.  I definitely used that line in my talk.  Here is a review article I recently published for the European Heart Journal about ACEi/ARBs and COVID-19: https://academic.oup.com/eurheartj/artic...51/5871935

[eyang1990]

I am a first time poster but long time viewer.  I felt it necessary to respond to this post.  As a cardiologist, we have witnessed many patients concerned about using these types of medications in light of COVID-19.  I can tell you that we don't have any data that indicates increased risk of these medications in COVID-19 patients.  In fact, there are some signals suggested possible benefits, but we will have to await the results of randomized clinical trials.  In general, ACE inhibitors and ARBS should not be discontinued for appropriate clinical indications.  I actually used your post in a presentation I did today on this topic (I hope you don't mind).  I hope this is helpful to the Stanford community.

Here is a link to the video: https://www.acc.org/latest-in-cardiology...t-thinking

Here is a good resource for patients and interested parties published on our cardiology website with up to date information:
https://www.acc.org/latest-in-cardiology...ar-disease

Haha, of course I don't mind, and thank you for your perspective. I'm tickled that your slide included that all-famous Cardboard phrase, "of immense proportions." I haven't watched your presentation yet, but I look forward to at some point, and I'm sure that your reference to my post was something like, "Here's GoodGrief's post--he must undoubtedly be the smartest and handsomest poster of our generation."

GoodGrief.  I definitely used that line in my talk.  Here is a review article I recently published for the European Heart Journal about ACEi/ARBs and COVID-19: https://academic.oup.com/eurheartj/artic...51/5871935